Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participan...

Full description

Bibliographic Details
Main Authors: Ya-Yen Yu, Shih-Ming Tsao, Wen-Ta Yang, Wei-Chang Huang, Ching-Hsiung Lin, Wei-Wen Chen, Shun-Fa Yang, Hui-Ling Chiou, Yi-Wen Huang
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:International Journal of Environmental Research and Public Health
Subjects:
drug metabolic enzymes
polymorphism
latent tuberculosis
adverse drug reaction
Online Access:https://www.mdpi.com/1660-4601/17/1/210

Internet

https://www.mdpi.com/1660-4601/17/1/210

Similar Items